GlassScriptPhysician profile
Mark A Goodrich
NPI 1356447882
$5,307.37
in general payments reported to CMS, 2019-2025
48 companies · $597 in 2025
The $597 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,165 · 2022: $1,166 · 2023: $829 · 2024: $1,550 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,976.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,170.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $734.88 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $371.54 | 2021-2025 | Mounjaro, Jardiance, Kisunla |
| Amgen INC. | $302.75 | 2021-2024 | Prolia, Evenity, Repatha |
| Axsome Therapeutics, INC. | $219.52 | 2023-2025 | Sunosi, Auvelity |
| Astellas Pharma US INC | $193.94 | 2021-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $191.55 | 2021-2023 | Xarelto, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $166.53 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $151.16 | 2021 | |
| Glaxosmithkline, LLC. | $144.66 | 2021-2023 | Shingrix, Arexvy, Bexsero |
| Novo Nordisk INC | $128.12 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $125.58 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $113.90 | 2021-2024 | Gardasil, Gardasil 9, Vaxelis |
| Otsuka America Pharmaceutical, INC. | $111.49 | 2022-2025 | Rexulti |
| Organon LLC | $86.57 | 2021-2024 | Nexplanon |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Goodrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.